What is the recommended treatment for heroin withdrawal in an adult?

Treatment of Heroin Withdrawal in Adults

Buprenorphine is the preferred first-line treatment for heroin withdrawal, superior to both nonopioid strategies and methadone in the acute setting. 1

Primary Treatment Approach

First-Line: Buprenorphine

• Buprenorphine should be used preferentially over methadone or nonopioid-based strategies for managing opioid withdrawal 1
• More effective than α2-adrenergic agonists (clonidine, lofexidine) combined with antiemetics, with less severe withdrawal symptoms, fewer adverse effects, and better treatment retention 1
• Safer discharge profile than methadone due to partial μ-receptor agonist activity, creating a ceiling effect on respiratory depression 1
• Reduces risk of opioid toxicity if patient uses additional opioids after discharge, unlike methadone's prolonged duration of action 1

Practical Buprenorphine Protocol

Timing is critical to avoid precipitated withdrawal: 1

• Wait >12 hours since last short-acting opioid use (heroin, morphine IR)
• Wait >24 hours for extended-release formulations
• Wait >72 hours for patients on methadone maintenance (consider methadone instead for these patients)

Assess withdrawal severity using Clinical Opioid Withdrawal Scale (COWS): 1

• COWS <8 (mild): No buprenorphine indicated; reassess in 1-2 hours
• COWS ≥8 (moderate to severe): Administer buprenorphine 4-8 mg sublingual based on severity; reassess after 30-60 minutes

Target dosing: 1

• Aim for 16 mg sublingual total for most patients on day 1
• Providers with X-waiver can prescribe 16 mg daily buprenorphine/naloxone for 3-7 days
• Non-waivered providers can administer (but not prescribe) for up to 3 consecutive days

Second-Line: Methadone

Methadone is similarly effective to buprenorphine for withdrawal management but carries greater safety concerns 1, 2:

• Can only be administered (not prescribed) for up to 72 hours without opioid treatment program participation 1
• Higher risk of opioid toxicity if patient uses additional opioids post-discharge due to long half-life 1
• Should be considered for patients on methadone maintenance (>72 hours since last dose) 1
• Less commonly used in emergency settings due to duration of action extending beyond the visit 1

Nonopioid Symptomatic Treatment (Third-Line)

When opioid agonist therapy is unavailable or contraindicated, use targeted symptom management 1:

• α2-adrenergic agonists: Clonidine or lofexidine for autonomic symptoms (avoid if hypotensive)
• Antiemetics: Promethazine or ondansetron for nausea/vomiting 1, 3
• Benzodiazepines: For anxiety, muscle cramps, and catecholamine release reduction
• Antidiarrheals: Loperamide for diarrhea
• Analgesics: Ibuprofen for pain 3

This approach is significantly less effective than opioid agonist therapy for withdrawal symptom control and treatment retention 1

Critical Safety Considerations

Precipitated Withdrawal Risk

• Buprenorphine can precipitate withdrawal if given before adequate withdrawal symptoms develop 1
• This complication can be overcome with sufficient buprenorphine dosing 1
• Always confirm adequate time since last opioid use and presence of objective withdrawal signs

Respiratory Depression

• Rare with buprenorphine monotherapy due to ceiling effect 1
• Risk increases significantly with concurrent benzodiazepines or other sedatives 1
• Methadone carries higher respiratory depression risk, especially with subsequent opioid use 1

Discharge Planning Essentials

• All patients should receive naloxone for overdose reversal 1, 3
• Provide overdose prevention education 1
• Offer hepatitis C and HIV screening 1
• Arrange follow-up for medication for opioid use disorder (MOUD) continuation 1

Long-Term Treatment Linkage

Withdrawal management alone is inadequate and dangerous 3, 2:

• Patients treated for acute withdrawal should be prescribed MOUD to decrease all-cause mortality (adjusted HR 0.52; 95% CI 0.42-0.63) 3
• Buprenorphine and methadone as maintenance therapy reduce overdose deaths and all-cause mortality 3, 2
• Withdrawal management as standalone intervention should be avoided 2
• Treatment retention is significantly improved when withdrawal management transitions directly to MOUD 1, 4